Recurrent disease following primary radiotherapy for localized prostate cancer is a common problem, occurring in up to 46% of patients. For these patients, therapeutic options include salvage prostatectomy, salvage cryotherapy, salvage high-intensity focused ultrasound (HIFU), hormonal therapy or observation. This review will focus on the emerging evidence for salvage HIFU. There are no randomized or prospective studies in this area. Efficacy results of 17-57% have been reported from retrospective case series, with reported toxicity including rectal fistula in 0-16%, and incontinence in 10-50%. The ideal patient, while yet to be clearly defined, should have preradiotherapy low or intermediate risk disease. Salvage HIFU appears most appropriate for those patients with histologically proven local recurrence only, with a life expectancy of at least 5 years and with some medical comorbidities rendering them not ideal for salvage prostatectomy.
Introduction
Biochemical failure after radiotherapy for localized prostate cancer is a frequent event. The ideal definition of biochemical recurrence is controversial and is constantly evolving (for example, three consecutive prostatespecific antigen (PSA) rises vs nadir þ 2 (ASTRO)). [1] [2] [3] [4] For external beam radiotherapy 5 the 7-year rate of biochemical failure ranges from 10 to 46% and for permanent prostate brachytherapy 6 the 8-year biochemical failure rate ranges from 26 to 61%. A recent publication from The Cancer of the Prostate Strategic Urological Research Endeavor database found an even higher biochemical failure rate of 63% in patients treated with external beam radiotherapy (EBRT). 7 This database is a longitudinal registry of men recruited from 31 centers throughout the United States, representing the broader community. Clearly the number of potential patients with local recurrence who are candidates for salvage therapy after radiation is large; however, Grossfeld et al. 8, 9 demonstrated that 92% of patients failing EBRT received androgen deprivation therapy for treatment of PSA failure. In a recent study with one of the largest cohorts, positive biopsy after radiotherapy was associated with an almost 3-fold increased risk of distant metastases and a 3.3-fold increased risk of prostate cancer related death. These data lend further support to aggressive local therapeutic interventions for clinically confined prostatic disease. 10 Salvage therapy can be local or systemic. Established local treatment options are salvage prostatectomy and salvage cryotherapy. These have the most mature data sets, and were traditionally associated with high morbidity rates, precluding wide usage in the salvage setting. 11, 12 In this setting, salvage high-intensity focused ultrasound (HIFU) was introduced, as a new local treatment modality, offering the possibility of a minimally invasive therapy with improved efficacy and lower morbidity.
HIFU has been extensively studied for the primary treatment of prostate cancer, 13 with recently published outcomes which are comparable to those of other minimally invasive therapies. The biochemical failurefree survival rates at 5 and 7 years have been reported at 77 and 69%, respectively.
14 In this paper we will review salvage HIFU as a promising minimally invasive alternative for the treatment of biochemical failure after primary radiotherapy for localized prostate cancer, and we will compare it with more recent results from salvage prostatectomy 15 and salvage cryotherapy 16 series.
Methods
A MEDLINE, PreMEDLINE and EMBASE review was performed using a combination of keywords ('High intensity focused ultrasound' or 'HIFU') and MeSH terms ('Ultrasound, High-Intensity Focused, Transrectal'). Articles were reviewed, any data applicable to the salvage setting was extracted and the bibliographies of relevant articles were also examined. In addition, the abstracts of the American Urological Association annual meeting, the European Association of Urology annual congress and the American Society of Clinical Oncology annual meeting were searched.
Preoperative assessment
Because of the potential morbidity of a salvage treatment, the crucial question is whether the biochemical recurrence is local or distant. Workup should include evaluation of clinical characteristics at initial diagnosis, serum PSA levels, computerized tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis, and local confirmation of recurrence with biopsy. 17 Patients with an initial presenting high-risk group (Gleason score X8, a clinical tumor category XT2c or a PSA level 420 ng ml
À1
. 18 ) have a shorter time to PSA failure, have a high rate of developing distant metastases 19 and most likely already harbor occult distant metastases, thus rendering these patients less ideal for local salvage therapy.
Laparoscopic pelvic lymph node dissection for restaging has been reported, although this may be technically difficult. 20, 21 Further studies in this area are needed, particularly with regards to the extent of lymph node dissection required, and to the potential role for laparoscopic sentinel node biopsy 22 in radiorecurrent prostate cancer.
PET/CT with F-fluorodeoxyglucose (tumor agent) and F-fluoride (bone agent) have both been used in the detection of extraprostatic disease, but their elimination is through the urinary tract and the overlapping signal can limit visualization. 23 Currently, bone scan is the most commonly used modality to assess for bony metastasis in the setting of radiorecurrent disease.
Single photon emission computerized tomography with indium-111 capromab pendetide (Prostascint) is undergoing further refinements, such as fusion with CT or MRI, 24, 25 which may improve its utility in detecting extraprostatic tumor involvement.
Physics and principles of HIFU
Ultrasound energy causes thermal (70-100 1C) and cavitational effects in the tissue, which undergo coagulative necrosis generating lesions in the focal point remote from the rectal probe. This effect is called an elemental lesion and is produced without damage to the organs in the path between the probe and the focal point. 26, 27 Geometrically, each elemental lesion is an ellipsoid, whose size is dependant on the crystal used in the transducer. 28 There is evidence that outcomes with HIFU are a direct dose-related effect.
Contraindications
Contraindications to HIFU in the primary treatment setting also apply in the salvage setting. In addition, supplementary precautions need to be considered. In the primary setting, prostate gland size should not exceed 40 ml; this can be reduced by performing transurethral resection of prostate (TURP) in the primary setting. However usually in the salvage setting the prostate size has already diminished due to the effects of radiotherapy. Other options to consider are a short course of androgen deprivation therapy. Relative contraindications include large volumes of intraprostatic calcifications, which can impair ultrasonic wave transmission. 29 Any rectal pathology can also be a contraindication in the primary setting. In the salvage setting, significant radiation proctitis and anal canal stenosis are definite contraindications.
Other contraindications in the salvage setting include inability to introduce the probe, inability to properly inflate the balloon due to poor elasticity of the rectal wall, bowel incontinence, severe hemorrhoids and a rectal wall which is too thick (46 mm). 27 
Special precautions
The boundaries of the prostate can be difficult to define after radiation and sometimes it is necessary to use a cystoscope to mark the apex to protect the sphincter. The treatment should start leaving a cranial 6 mm margin. Once the boundaries are established using ultrasound imaging a safety margin of between 3-6 mm is allowed to protect the rectal mucosa. Also, the hypovascularization of the irradiated tissue requires adapting the acoustic parameters, as the pretreated tissues have less heat conduction generating higher temperatures. The recommendation, therefore, is to decrease the shot duration from 4.5 to 4 s and increase the shot interval from 5 to 7 s. 27, 30, 31 The effect of brachytherapy seeds on salvage HIFU has been assessed, using bovine liver. The authors demonstrated a significant effect of the seeds on the HIFU focal region, as well as a reduction in lesion length when the seeds were placed in a pre-focal position. 32 Special attention is needed for salvage HIFU in the presence of interstitial seeds, where adjustment of power wattage may be necessary.
Preservation of the neurovascular bundle (that is, leaving areas without treatment) is correlated with less biochemical and histological control. 33 The surgeon should have detailed preoperative discussion with the patient regarding nerve-sparing strategies, taking into account the tumor extent, the likelihood of success of erectile function preservation and patient preference.
Transurethral resection of prostate
Necrotic tissue was associated in many series of primary HIFU with urinary tract obstruction, due to necrotic debris and edema in a third of the patients. 34 In the salvage setting the irradiated prostates are small, and so TURP is only considered if an obstructive middle lobe is present. A high risk of incontinence has been reported if standard TURP is carried out before HIFU in the salvage setting. 27 
Efficacy
There are currently no clear cut criteria with which to define failure after salvage HIFU; indeed, the definition of failure after primary HIFU is still unclear, with some authors using biopsy results and other authors using the Role of salvage HIFU V Chalasani et al ASTRO Phoenix definition. 35, 36 Nevertheless, the postsalvage HIFU biopsy is a clear cut first end point, as the reported series use different definitions for biochemical recurrence (Tables 1 and 2) .
Several published abstracts have commented on performing salvage HIFU, however specific numbers were not available in the abstracts. Success rates of up to 50% at 12 months have been noted in such abstracts. 47, 48 The largest published series of salvage HIFU to date, from Murat et al., 49 included 167 patients treated between 1995 and 2006. The majority of the patients underwent a single treatment; however 27 patients underwent a repeat procedure. Biopsies were performed on all patients at 3 months, as well as for a rising PSA. The negative biopsy rate was 73%, and the 5-year estimated overall survival was 84% (Kaplan-Meier). The ASTRO Phoenix 4 definition of failure was used when calculating progression free survival, and patients were stratified according to their preradiotherapy D'Amico risk classification. 18 The 3-year progression-free survival was 53% for low risk patients, 42% for intermediate risk patients and 25% for high risk patients.
Complications/toxicity of salvage HIFU
Chaussy et al. 50 reported on the overall complications noted in over 1500 primary and salvage HIFU treatments performed since 1996. They noted that the complication rate increased with the number of previous therapies (such as radiotherapy). However a breakdown of complications was not available. D'Hont et al. 51 noted no major complications in their series of 350 patients, although the abstract did not state how many patients were salvages vs primary therapy. In a follow-up report of 450 patients, they again commented that in their series salvage HIFU was a safe option. 52 The largest published series (Table 3) , involving 167 patients, noted urinary retention in 7.8% and urinary tract infections in 3.5%. 49 After 2002, the authors changed the acoustic parameters used to deliver the HIFU, and noted a significant reduction in urethrorectal fistula (5 vs 0 patients), artificial sphincter implantation (20 vs 6%), and bladder outlet obstruction (30 vs 14.5%). They did not evaluate erectile function in the salvage setting. 49 The main alternatives to salvage HIFU, namely salvage radical prostatectomy and cryotherapy, have experienced reduced morbidity rates in recent years. 57 The recently published complication rates of salvage radical prostatectomy show rectal injury rates of 0-4%, incontinence rates of 17-55% and anastomotic strictures in 0-41% of patients. [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] In modern cryotherapy series, the reported rates of complications were rectal fistula in 0-1%, incontinence in 13-17% and perineal pain in 4-5.6%. 67, 68 The age and performance status of the salvage prostatectomy and Role of salvage HIFU V Chalasani et al salvage cryotherapy groups appear somewhat different, with cryotherapy being more suitable to the older patients and those with some comorbidities (for example, life expectancy 45 years for salvage cryotherapy vs 410 years for salvage prostatectomy). As the two modalities appear to be similar in terms of invasiveness and have comparable morbidities, salvage HIFU appears to be suitable for the salvage cryotherapy cohort. In summary, the major complications of salvage HIFU are rectal fistula rates of 0-16%, and incontinence reported in 10-49.5% of patients. The authors of all salvage HIFU series have noted that their major complications tended to occur early in their experience.
Prognostic factors
Murat et al., 69 in a series of 167 patients, reported that patients most likely to benefit from salvage HIFU were those who had not had previous hormones, and those with preradiotherapy low or intermediate risk disease. The pre-HIFU biopsy Gleason score and the positive biopsy percentage did not influence the progression free survival rate. Seo et al., 41 in their series of 30 patients, found that the PSA nadir level was the only significant predictor on multivariate analysis.
Studies in progress
There is an ongoing phase II trial at the University of Western Ontario (Canada) entitled 'Feasibility Study for Locally Recurrent Prostate Cancer Treatment Following Radiation Failure With High Intensity Focused Ultrasound' (clinicaltrials.gov identifier NCT00318240). The inclusion criteria for this open label study are patients with biopsy proven recurrence following radiotherapy, with a serum PSA between 0.5-10, and a preradiation Gleason score of o8. Recently, the FDA has given approval for a trial in the treatment of recurrent prostate cancer with the Sonablate 500, at several sites in the USA, in patients who have failed external beam radiotherapy.
Conclusions
The management of the patient with recurrent prostate cancer following radiotherapy is a challenging clinical problem. Salvage HIFU is in its infancy, and the reported literature (a significant proportion which is in abstract form only) includes mainly small single center series. Nevertheless, early results appear promising, with morbidity decreasing. As with other salvage treatment options, meticulous patient selection is the key to success. Salvage HIFU appears most appropriate for those patients with histologically proven local recurrence only, with a life expectancy of at least 5 years and with some medical comorbidities rendering them not ideal for salvage prostatectomy. Furthermore, the best results appear to be in patients who are hormone naive, and have preradiotherapy low or intermediate risk disease. Further phase II studies with long-term follow-up are needed. A phase III trial comparing salvage HIFU to hormones or salvage cryotherapy would be welcomed to further define the role of HIFU in those patients who have clinically localized recurrent or persistent prostate cancer following radiation therapy.
